Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications.

Cytokines and Chemokines in HBV Infection

Advances in Hepatitis B Treatment

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Antibody-mediated immunotherapy against chronic hepatitis B virus infection.

Novel Approaches Towards Conquering Hepatitis B Virus Infection

New advances in drug therapy of chronic hepatitis B infection

Anti-hepatitis B virus activities of natural products and their antiviral mechanisms

Progress in therapeutic monoclonal antibodies targeting hepatitis B surface antigen

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

Emerging Antivirals for the Treatment of Hepatitis B

Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.

Current Advances in the Elimination of Hepatitis B in China by 2030

Fighting the Hepatitis B Virus: Past, Present & Future

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

New progress and opinions of the immunological response for HBV infection

Development of novel therapeutics for chronic hepatitis B

Recent Advances in Screening Methods Enabling the Discovery of Novel Anti-Hepatitis B Virus Drug Candidates

Present and Future Therapies for Chronic Hepatitis B.

The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies